In this study, a reliable method for the quantitation of (E)-N-benzyl-6-[2-(3, 4-dihydroxy benzylidene)hydrazinyl]-N-methylpyridine-3-sulfonamide (JW-55) in rat plasma was developed and validated using high-performance liquid chromatography. Plasma samples were deproteinized; sildenafil was used as an internal standard. Chromatographic separation was achieved using a reversed-phase C18 column. The mobile phase, 0.02 m ammonium acetate buffer:acetonitrile (48:52, v/v), was run at a flow rate of 1.0 mL/min at room temperature, and the column eluent was monitored using an ultraviolet detector at 280 nm. The retention times of JW-55 and sildenafil were ~5.9 and 7.7 min, respectively. The detection limit of JW-55 in rat plasma was 0.03 μg/mL. Pharmacokinetic parameters of JW-55 were evaluated after intravenous and oral administration of JW-55 (10 mg/kg) in rats. After oral administration, the F value was approximately 73.7%.
Keywords: HPLC; Rab27a; bioavailability; intracellular membrane trafficking; protein-protein blocker; rats.
Copyright © 2016 John Wiley & Sons, Ltd.